Breast Cancer | Specialty

Combination Regimens May Expand Options for HR+ Breast Cancer Post-CDK4/6 Inhibitors

August 23rd 2024

Shipra Gandhi, MD, discusses factors influencing treatment decisions for patients with HR-positive breast cancer who have progressed on CDK4/6 inhibitors.

Weighing the Options: Considerations for Adjuvant CDK4/6 Inhibitor Selection in HR+ Breast Cancer

August 23rd 2024

Jason A. Mouabbi, MD, discusses novel endocrine and targeted therapies that may overcome CDK4/6 resistance in HR-positive, HER2-negative breast cancer.

Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer

August 22nd 2024

Dr Jhaveri discusses the INAVO120 trial of inavolisib plus palbociclib and fulvestrant in PIK3CA-mutant, HR-positive metastatic breast cancer.

The HR-Positive Breast Cancer Treatment Paradigm Sits on the Cusp of Significant Shifts

August 22nd 2024

Shipra Gandhi, MD, highlights findings with oral SERDs in HR-positive breast cancer and options to consider after progression on CDK4/6 inhibitors.

A New Wave of Endocrine Therapies Are Emerging in HR+ Breast Cancer

August 21st 2024

Jason A. Mouabbi, MD, discusses novel endocrine and targeted therapies that may overcome CDK4/6 resistance in HR-positive, HER2-negative breast cancer.

ADCs in Breast Cancer: Mechanism of Action, and Components

August 21st 2024

Medical experts discuss the distinct mechanisms and components of different antibody-drug conjugates (ADCs), including the drug, antibody, and linker, and how these components contribute to the mechanisms of ADC-related toxicities.

Overview of Current ADCs in Breast Cancer

August 21st 2024

Medical experts review the currently available antibody-drug conjugates for breast cancer, including Sacituzumab govitecan (Trop-2 directed ADC), Kadcyla (ado-trastuzumab emtansine, T-DM1, HER2-directed ADC), and Enhertu (fam-trastuzumab deruxtecan-nxki, T-DXd, HER2-directed ADC).

Dr Yee on Neoadjuvant Datopotamab Deruxtecan Plus Durvalumab in Early-Stage Breast Cancer

August 20th 2024

Douglas Yee, MD, discusses datopotamab deruxtecan and durvalumab in the neoadjuvant setting for early-stage breast cancer.

Awareness Efforts Needed to Address Genetic Testing Disparities Among Male BRCA1/2 Carriers

August 20th 2024

Males harboring BRCA1/2 pathologic variants have a higher risk of developing select cancers but are less likely to undergo genetic testing.

FDA Lifts Partial Clinical Hold on Phase 1 Trial of YL202 in Advanced NSCLC and Breast Cancer

August 19th 2024

The FDA has lifted a partial clinical hold on the phase 1 trial evaluating YL202 in advanced breast cancer and EGFR-mutated non–small cell lung cancer.

Copper Depletion Combats Metastatic Recurrence in High-Risk TNBC

August 17th 2024

Linda T. Vahdat, MD, discusses research with copper depletion in patients with high-risk triple-negative breast cancer.

Dr Hursting on Weight Loss Drugs and the Potential to Reduce Obesity-Related Breast Cancer

August 15th 2024

An Embarrassment of Riches in Oncology With Wayward Decision Support: A Recipe for Disaster?

August 15th 2024

Head over to our YouTube channel to watch Dr Markman discuss the effects of information overload in oncology: https://rb.gy/bvumdn.

Ongoing Research Aims to Unveil the Optimal Use of Neoadjuvant and Adjuvant Therapies in TNBC

August 15th 2024

Linda T. Vahdat, MD, discusses investigations of ADCs and targeted agents in patients with TNBC and residual disease following chemoimmunotherapy.

Dr Kalinsky on Unmet Needs and Findings from RxPONDER in HR+/HER2– Breast Cancer

August 15th 2024

Kevin Kalinsky, MD, MS, discusses AMH levels and responses in premenopausal HR+/HER2–, node-positive breast cancer.

Dr Mouabbi on Challenges Diagnosing and Managing Invasive Lobular Carcinoma

August 14th 2024

Jason A. Mouabbi, MD, discusses challenges associated with diagnosing and managing invasive lobular carcinoma

FDA Grants Fast Track Status to AC699 for ER+/HER2–, ESR1-Mutated Breast Cancer

August 14th 2024

AC699 has won fast track designation from the FDA for select patients with ER-positive, HER2-negative, ESR1-mutated breast cancer.

Dr Feldman on the Prevention and Management of Breast Cancer–Related Lymphedema

August 14th 2024

Sheldon Feldman, MD, discusses prevention and management strategies for breast cancer–related lymphedema.

Dr Thompson on the Necessity of Surgery and Radiation Therapy in Early-Stage Breast Cancer

August 14th 2024

Alastair Thompson, BSc, MBChB, MD, FRCS, discusses ongoing challenges in determining the optimal treatment strategy for patients with early-stage breast cancer.

Dr Yee on Neoadjuvant Datopotamab Deruxtecan in High-Risk, Early-Stage Breast Cancer

August 13th 2024

Douglas Yee, MD, discusses neoadjuvant datopotamab deruxtecan in early-stage breast cancer